JP2015527321A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527321A5 JP2015527321A5 JP2015521771A JP2015521771A JP2015527321A5 JP 2015527321 A5 JP2015527321 A5 JP 2015527321A5 JP 2015521771 A JP2015521771 A JP 2015521771A JP 2015521771 A JP2015521771 A JP 2015521771A JP 2015527321 A5 JP2015527321 A5 JP 2015527321A5
- Authority
- JP
- Japan
- Prior art keywords
- laquinimod
- pharmaceutical composition
- stable pharmaceutical
- lubricant
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 78
- 229960004577 laquinimod Drugs 0.000 claims description 67
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims description 58
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 34
- 239000000945 filler Substances 0.000 claims description 29
- 239000000314 lubricant Substances 0.000 claims description 28
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 23
- 229930195725 Mannitol Natural products 0.000 claims description 23
- 239000000594 mannitol Substances 0.000 claims description 23
- 235000010355 mannitol Nutrition 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 235000019359 magnesium stearate Nutrition 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000002265 redox agent Substances 0.000 claims description 14
- 230000003113 alkalizing effect Effects 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- JWHPPWBIIQMBQC-UHFFFAOYSA-M sodium;5-chloro-3-[ethyl(phenyl)carbamoyl]-1-methyl-2-oxoquinolin-4-olate Chemical compound [Na+].[O-]C=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 JWHPPWBIIQMBQC-UHFFFAOYSA-M 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002274 desiccant Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 3
- 229960001021 lactose monohydrate Drugs 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229960004977 anhydrous lactose Drugs 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000007857 degradation product Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000000905 isomalt Substances 0.000 claims description 2
- 235000010439 isomalt Nutrition 0.000 claims description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims description 2
- 229910003002 lithium salt Inorganic materials 0.000 claims description 2
- 159000000002 lithium salts Chemical group 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000227 grinding Methods 0.000 claims 1
- 239000008190 ground granulate Substances 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261670268P | 2012-07-11 | 2012-07-11 | |
| US61/670,268 | 2012-07-11 | ||
| PCT/US2013/049894 WO2014011750A1 (en) | 2012-07-11 | 2013-07-10 | Laquinimod formulations without alkalizing agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015527321A JP2015527321A (ja) | 2015-09-17 |
| JP2015527321A5 true JP2015527321A5 (https=) | 2016-09-01 |
Family
ID=49914501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521771A Pending JP2015527321A (ja) | 2012-07-11 | 2013-07-10 | アルカリ化剤を含まないラキニモド製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140018386A1 (https=) |
| EP (1) | EP2872141A4 (https=) |
| JP (1) | JP2015527321A (https=) |
| KR (1) | KR20150036553A (https=) |
| CN (1) | CN104470519A (https=) |
| AR (1) | AR091706A1 (https=) |
| AU (1) | AU2013290274A1 (https=) |
| BR (1) | BR112015000321A2 (https=) |
| CA (1) | CA2873230A1 (https=) |
| EA (1) | EA201590193A1 (https=) |
| HK (1) | HK1209054A1 (https=) |
| IL (1) | IL236229A0 (https=) |
| MX (1) | MX2015000398A (https=) |
| NZ (1) | NZ630241A (https=) |
| SG (2) | SG10201700198VA (https=) |
| TW (1) | TW201408299A (https=) |
| UA (1) | UA115555C2 (https=) |
| WO (1) | WO2014011750A1 (https=) |
| ZA (1) | ZA201500287B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2445451T3 (es) | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| JP2015535287A (ja) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドのアミン塩 |
| NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| CN107823168A (zh) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | 一种快速溶解的片剂及其制备方法 |
| CN107823150A (zh) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | 一种可快速分散的片剂及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US7884208B2 (en) * | 2005-10-19 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
| RS52169B (sr) * | 2006-06-12 | 2012-08-31 | Teva Pharmaceutical Industries Limited | Stabilni preparati lakvinimoda |
| ES2445451T3 (es) * | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| WO2010070449A2 (en) * | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| WO2013016686A1 (en) * | 2011-07-28 | 2013-01-31 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
-
2013
- 2013-07-08 AR ARP130102429 patent/AR091706A1/es unknown
- 2013-07-09 TW TW102124610A patent/TW201408299A/zh unknown
- 2013-07-10 SG SG10201700198VA patent/SG10201700198VA/en unknown
- 2013-07-10 EA EA201590193A patent/EA201590193A1/ru unknown
- 2013-07-10 KR KR1020157003693A patent/KR20150036553A/ko not_active Withdrawn
- 2013-07-10 EP EP13816725.9A patent/EP2872141A4/en not_active Withdrawn
- 2013-07-10 BR BR112015000321A patent/BR112015000321A2/pt active Search and Examination
- 2013-07-10 MX MX2015000398A patent/MX2015000398A/es unknown
- 2013-07-10 HK HK15109818.4A patent/HK1209054A1/xx unknown
- 2013-07-10 JP JP2015521771A patent/JP2015527321A/ja active Pending
- 2013-07-10 AU AU2013290274A patent/AU2013290274A1/en not_active Abandoned
- 2013-07-10 CN CN201380027660.2A patent/CN104470519A/zh active Pending
- 2013-07-10 NZ NZ630241A patent/NZ630241A/en not_active IP Right Cessation
- 2013-07-10 SG SG11201407688QA patent/SG11201407688QA/en unknown
- 2013-07-10 WO PCT/US2013/049894 patent/WO2014011750A1/en not_active Ceased
- 2013-07-10 CA CA2873230A patent/CA2873230A1/en not_active Abandoned
- 2013-07-10 US US13/938,733 patent/US20140018386A1/en not_active Abandoned
- 2013-10-07 UA UAA201413984A patent/UA115555C2/uk unknown
-
2014
- 2014-12-14 IL IL236229A patent/IL236229A0/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00287A patent/ZA201500287B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015527321A5 (https=) | ||
| JP5421775B2 (ja) | オキシコドンを含む顆粒及び口腔内崩壊錠剤 | |
| EP2842549B1 (en) | Orally disintegrating tablet and method for producing same | |
| ES3048688T3 (en) | High dosage strength tablets of rucaparib | |
| CN101420982B (zh) | 干式直压速崩片 | |
| ES2453477T3 (es) | Composición de excipiente coprocesada para un comprimido, su preparación y uso | |
| KR20100121509A (ko) | 구강 내 붕괴정 | |
| JP6724114B2 (ja) | 硫酸塩の両用経口薬学的組成物錠剤およびその使用の方法 | |
| JP5870690B2 (ja) | 口腔内崩壊錠及びその製造方法 | |
| WO2019151405A1 (ja) | 錠剤及びその製造方法 | |
| JP2011513194A (ja) | 口腔内崩壊錠 | |
| JP2013533881A (ja) | バノキセリンを含有する医薬組成物 | |
| JP4812626B2 (ja) | 口腔内溶解用固形製剤 | |
| JP2010202579A (ja) | アカルボースを含有する口腔内崩壊剤 | |
| KR101567937B1 (ko) | 안정성이 개선된 다층 고형 제제 | |
| AU2013250251A1 (en) | Encapsulated formulation | |
| JP2017066133A (ja) | 安定性及び速効性の高いイブプロフェン含有固形製剤 | |
| JP2007332063A (ja) | ポビドンヨードを含有する口腔内崩壊型固形製剤 | |
| WO2025120308A1 (en) | An orally disintegrating tablet of paroxetine and its process of preparation | |
| JP5270838B2 (ja) | トロキシピドを含有する胃粘膜障害治療剤 | |
| CN101134013B (zh) | 口服用制剂 | |
| WO2014171306A1 (ja) | 小動物への投与に適した速崩壊錠とその簡便な製造方法 | |
| JP2013049723A (ja) | トロキシピドを含有する胃粘膜障害治療剤 | |
| HK1206983B (en) | Orally disintegrating tablet and method for producing same | |
| CN104644644A (zh) | 一种富马酸喹硫平药物组合物 |